Aspira Women’s Health names new fractional CFO

Aspira Women’s Health Inc. appointed John Strahley as Chief Financial Officer and Chief Accounting Officer, effective April 27, 2026, replacing Brian Hungerford, who stepped down for personal reasons.

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

8-K

Rhea-AI Filing Summary

Aspira Women’s Health Inc. appointed John Strahley as Chief Financial Officer and Chief Accounting Officer, effective April 27, 2026, replacing Brian Hungerford, who stepped down for personal reasons. Strahley will work in a fractional role, committing at least twenty hours per week.

Under his Executive Employment Agreement, Strahley receives an annualized base salary of $167,000 and is eligible for the company’s 401(k) plan but not for group insurance benefits. The Board will approve stock options for 70,000 shares at fair market value on the grant date, with 25% vesting ninety days after his start date and the remainder vesting monthly over the following nine months. Any unvested options fully vest upon a Change in Control, and his at-will employment includes no severance beyond accrued obligations.

8-K Event Classification

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

1 item

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Key Figures

CFO base salary: $167,000 per year Stock options grant: 70,000 shares Minimum weekly hours: 20 hours per week +4 more

7 metrics

CFO base salary $167,000 per year Annualized base salary for John Strahley as CFO

Stock options grant 70,000 shares Options to purchase common stock under equity incentive plan

Minimum weekly hours 20 hours per week Fractional capacity commitment in Employment Agreement

Initial vesting milestone 25% after 90 days Portion of options vesting ninety days after employment start

Remaining vesting period 9 months Remaining 75% of options vest monthly over nine months

Effective CFO start date April 27, 2026 Date Strahley becomes CFO and Chief Accounting Officer

Prior CFO agreement end date April 26, 2026 Termination of Hungerford Consulting LLC agreement

Key Terms

fractional capacity, Executive Employment Agreement, equity incentive plan, Change in Control, +2 more

6 terms

fractional capacity financial

"Mr. Strahley will serve in a fractional capacity, devoting a minimum of twenty hours per week"

Executive Employment Agreement regulatory

"the Company entered into an Executive Employment Agreement (the "Employment Agreement") with John Strahley"

equity incentive plan financial

"options to purchase 70,000 shares of the Company's common stock under the Company's equity incentive plan"

An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.

Change in Control financial

"Upon a Change in Control of the Company, one hundred percent of any then-unvested options will accelerate"

A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.

at-will regulatory

"Mr. Strahley's employment is at-will and may be terminated by either party at any time"

Item 404(a) of Regulation S-K regulatory

"There are no transactions in which Mr. Strahley has an interest requiring disclosure under Item 404(a) of Regulation S-K"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What executive change did Aspira Women’s Health (AWHL) disclose?

Aspira Women’s Health appointed John Strahley as Chief Financial Officer and Chief Accounting Officer, effective April 27, 2026, replacing Brian Hungerford. Hungerford’s consulting agreement ended April 26, 2026, at the request of Hungerford Consulting LLC, with his departure described as for personal reasons.

What is the compensation package for AWHL’s new CFO John Strahley?

John Strahley will receive an annualized base salary of $167,000, paid semi-monthly. He is eligible to participate in Aspira Women’s Health’s 401(k) plan but not in its group health, dental, vision, or life insurance plans under his Executive Employment Agreement.

What stock options will AWHL grant to new CFO John Strahley?

Aspira Women’s Health’s Board will approve options for 70,000 shares of common stock for John Strahley, with an exercise price equal to fair market value on the grant date. The options are granted under the company’s equity incentive plan, subject to the described vesting schedule.

How do John Strahley’s stock options at AWHL vest over time?

Twenty-five percent of John Strahley’s 70,000 stock options vest ninety days after his employment start date. The remaining seventy-five percent vest in equal monthly installments during the following nine months, conditioned on his continued employment on each monthly vesting date.

What happens to AWHL CFO John Strahley’s options in a Change in Control?

If Aspira Women’s Health undergoes a Change in Control, one hundred percent of John Strahley’s then-unvested stock options will accelerate and become fully vested. This provision gives him immediate ownership of all outstanding options upon such a corporate transaction, as defined in the plan.

Is AWHL CFO John Strahley’s employment full-time and does he receive severance?

John Strahley serves in a fractional capacity, devoting a minimum of twenty hours per week to his CFO and Chief Accounting Officer duties. His employment is at-will and may be terminated by either party at any time, with no severance or post-termination benefits beyond accrued obligations.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 04/30/2026 - 04:56 PM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): April 26, 2026

ASPIRA WOMEN’S HEALTH INC.

(Exact name of registrant as specified in its charter)


Delaware		001-34810		33-0595156
(State or other jurisdiction of		(Commission		(IRS Employer
incorporation or organization)		File Number)		Identification No.)

12117 Bee Caves Road, Building III, Suite 100

Austin, TX 78738

(Address of principal executive office) (Zip Code)

(512) 519-0400

(Registrants’ telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.001	AWHL	OTC QX Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter)

Emerging Growth Company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On April 26, 2026, Aspira Women's Health, Inc. (the "Company") appointed John Strahley as Chief Financial Officer and Chief Accounting Officer of the Company, effective April 27, 2026. In connection with Mr. Strahley's appointment, the consulting agreement under which Brian Hungerford had served as Chief Financial Officer terminated effective April 26, 2026.

Appointment of Principal Financial Officer and Chief Accounting Officer

On April 26, 2026, the Company entered into an Executive Employment Agreement (the "Employment Agreement") with John Strahley, pursuant to which Mr. Strahley was appointed as Chief Financial Officer and Chief Accounting Officer of the Company, effective April 27, 2026.

Mr. Strahley, age 59, brings extensive financial leadership experience to the Company. Prior to joining the Company, Mr. Strahley served as CFO of several life science companies, including IsoPlexis Corporation. He previously served as a Managing Director at Ironwood Capital and Senior Vice President at Webster Bank. He began his career as a Certified Public Accountant.

There are no arrangements or understandings between Mr. Strahley and any other persons pursuant to which he was appointed to his positions with the Company. There are no family relationships between Mr. Strahley and any director or executive officer of the Company. There are no transactions in which Mr. Strahley has an interest requiring disclosure under Item 404(a) of Regulation S-K.

Pursuant to the Employment Agreement, Mr. Strahley will serve in a fractional capacity, devoting a minimum of twenty hours per week to his duties. The Employment Agreement provides for an annualized base salary of $167,000, payable on a semi-monthly basis. Mr. Strahley is not eligible to participate in the Company's group health, dental, vision, or life insurance plans, but is eligible to participate in the Company's 401(k) plan in accordance with its terms.

In connection with his appointment, the Board of Directors of the Company will approve a grant to Mr. Strahley of options to purchase 70,000 shares of the Company's common stock under the Company's equity incentive plan as soon as administratively possible, with an exercise price equal to the fair market value of the Company's common stock on the grant date.. Twenty-five percent of the options will vest ninety days after Mr. Strahley's employment start date, with the remaining seventy-five percent vesting in equal monthly installments over the following nine months, subject to Mr. Strahley's continued employment on each vesting date. Upon a Change in Control of the Company, one hundred percent of any then-unvested options will accelerate and become fully vested.

Mr. Strahley's employment is at-will and may be terminated by either party at any time. Mr. Strahley is not entitled to any severance or post-termination benefits beyond accrued obligations.

The foregoing description of the Employment Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Employment Agreement, a copy of which will be filed as an exhibit to the Company's Quarterly Report on Form 10-Q for the quarter ending June 30, 2026.

Departure of Principal Financial Officer

On April 26, 2026, the consulting agreement between the Company and Hungerford Consulting LLC, under which Brian Hungerford had served as Chief Financial Officer, terminated at the request of Hungerford Consulting LLC. Mr. Hungerford is departing from his role as Chief Financial Officer for personal reasons. The Company thanks Mr. Hungerford for his service and contributions and wishes him well in his future endeavors.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Dated: April 30, 2026


	ASPIRA WOMEN’S HEALTH INC.

	By:	/s/ Michael Buhle
	Name:	Michael Buhle
	Title:	Chief Executive Officer

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

3 documents